Advertisement
Advertisement
NAGE
Niagen Bioscience, Inc. Common Stock
3.76
USDSponsored
-0.09
-2.34%
May 13, 16:00 UTC -4
Closed
Pre-Market
3.85
+0.09
+2.37%
NAGE Earnings Reports
Positive Surprise Ratio
NAGE beat 22 of 38 last estimates.
58%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$32.70M
/$0.02
Implied change from Q1 26 (Revenue/ EPS)
+3.89%
/-71.43%
Implied change from Q2 25 (Revenue/ EPS)
+5.08%
/-50.00%
Niagen Bioscience, Inc. Common Stock earnings per share and revenue
On May 06, 2026, NAGE reported earnings of 0.07 USD per share (EPS) for Q1 26, beating the estimate of 0.06 USD, resulting in a 0.86% surprise. Revenue reached 31.47 million, compared to an expected 31.57 million, with a -0.30% difference. The market reacted with a -15.69% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of 0.02 USD, with revenue projected to reach 32.70 million USD, implying an decrease of -71.43% EPS, and increase of 3.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Niagen Bioscience, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Niagen Bioscience, Inc. Common Stock reported EPS of $0.07, beating estimates by 0.86%, and revenue of $31.47M, -0.3% below expectations.
How did the market react to Niagen Bioscience, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -15.69%, changed from $4.97 before the earnings release to $4.19 the day after.
When is Niagen Bioscience, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Niagen Bioscience, Inc. Common Stock's next earnings report?
Based on 5
analysts, Niagen Bioscience, Inc. Common Stock is expected to report EPS of $0.02 and revenue of $32.70M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement